Beauty Of Amgen Bone Drug Results Is In Eye Of The Beholder

Top-line results from Phase III bone metastasis prevention trial lift stock price and inspire bullish headlines for Amgen. But vital figures and proof of clinical benefit are missing, making study tougher to interpret.